Intradiscal Gelified Ethanol and Pulsed Radiofrequency Versus Gelified Ethanol Injection for Discogenic Low Back Pain
Launched by ATTIKON HOSPITAL · Jan 16, 2015
Trial Information
Current as of August 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Discogenic low back pain \> 6 months,
- • pain refractory to conservative treatment,
- • no other aetiology for pain,
- • pain reported during provocative discography according to standard criteria,
- • MRI imaging indicating disk degenarative disease
- Exclusion Criteria:
- • Red flags for low back pain,
- • lumbosacral radiculopathy,
- • extruded or sequestered lumbar disc,
- • severe spinal stenosis,
- • facet joint syndrome,
- • sacroiliac joint pain,
- • neurological disorders,
- • psychiatric disorders,
- • rheumatoid arhtritis, ancylosing spondylitis, other autoimmune arthritis,
- • coagulation disorders,
- • pregnancy
About Attikon Hospital
Attikon Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research. With a strong commitment to patient-centered care, the hospital actively sponsors clinical trials that aim to evaluate new therapeutic interventions and improve treatment outcomes across various medical fields. Attikon Hospital leverages its state-of-the-art facilities and a multidisciplinary team of experienced healthcare professionals to ensure rigorous study design, ethical standards, and comprehensive patient safety. By fostering collaboration among researchers, clinicians, and patients, Attikon Hospital plays a pivotal role in translating scientific discoveries into effective clinical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials